<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38945449</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>300</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Mechanism and spectrum of inhibition of a 4'-cyano modified nucleotide analog against diverse RNA polymerases of prototypic respiratory RNA viruses.</ArticleTitle><Pagination><StartPage>107514</StartPage><MedlinePgn>107514</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">107514</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbc.2024.107514</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0021-9258(24)02015-5</ELocationID><Abstract><AbstractText>The development of safe and effective broad-spectrum antivirals that target the replication machinery of respiratory viruses is of high priority in pandemic preparedness programs. Here, we studied the mechanism of action of a newly discovered nucleotide analog against diverse RNA-dependent RNA polymerases (RdRps) of prototypic respiratory viruses. GS-646939 is the active 5'-triphosphate metabolite of a 4'-cyano modified C-adenosine analog phosphoramidate prodrug GS-7682. Enzyme kinetics show that the RdRps of human rhinovirus type 16 (HRV-16) and enterovirus 71 incorporate GS-646939 with unprecedented selectivity; GS-646939 is incorporated 20-50-fold more efficiently than its natural ATP counterpart. The RdRp complex of respiratory syncytial virus and human metapneumovirus incorporate GS-646939 and ATP with similar efficiency. In contrast, influenza B RdRp shows a clear preference for ATP and human mitochondrial RNA polymerase does not show significant incorporation of GS-646939. Once incorporated into the nascent RNA strand, GS-646939 acts as a chain terminator although higher NTP concentrations can partially overcome inhibition for some polymerases. Modeling and biochemical data suggest that the 4'-modification inhibits RdRp translocation. Comparative studies with GS-443902, the active triphosphate form of the 1'-cyano modified prodrugs remdesivir and obeldesivir, reveal not only different mechanisms of inhibition, but also differences in the spectrum of inhibition of viral polymerases. In conclusion, 1'-cyano and 4'-cyano modifications of nucleotide analogs provide complementary strategies to target the polymerase of several families of respiratory RNA viruses.</AbstractText><CopyrightInformation>Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Calvin J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Simon M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tchesnokov</LastName><ForeName>Egor P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kocincova</LastName><ForeName>Dana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pitts</LastName><ForeName>Jared</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc, Foster City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siegel</LastName><ForeName>Dustin S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc, Foster City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>Jason K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc, Foster City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Joy Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc, Foster City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilello</LastName><ForeName>John P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Inc, Foster City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Götte</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada. Electronic address: gotte@ualberta.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AI171292</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber><NameOfSubstance UI="D012324">RNA-Dependent RNA Polymerase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009711">Nucleotides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012324" MajorTopicYN="Y">RNA-Dependent RNA Polymerase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012328" MajorTopicYN="N">RNA Viruses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029121" MajorTopicYN="N">Metapneumovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009711" MajorTopicYN="N">Nucleotides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">RNA virus</Keyword><Keyword MajorTopicYN="N">RNA-dependent RNA polymerase</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">influenza virus</Keyword><Keyword MajorTopicYN="N">nucleotide analog</Keyword><Keyword MajorTopicYN="N">pandemic preparedness</Keyword><Keyword MajorTopicYN="N">prototypic pathogens</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword><Keyword MajorTopicYN="N">respiratory syncytial virus</Keyword><Keyword MajorTopicYN="N">respiratory viruses</Keyword><Keyword MajorTopicYN="N">rhinovirus</Keyword></KeywordList><CoiStatement>Conflict of interest M. G. received funding from Gilead Sciences in support for studies on the mechanism of action of nucleotide analog polymerase inhibitors. J. P., D. S. S., J. K. P., J. Y. F., and J. P. B. are current or former Gilead employees.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>30</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38945449</ArticleId><ArticleId IdType="pmc">PMC11345399</ArticleId><ArticleId IdType="doi">10.1016/j.jbc.2024.107514</ArticleId><ArticleId IdType="pii">S0021-9258(24)02015-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., et al. A novel coronavirus from patients with pneumonia in China, 2019. New Engl. J. Med. 2020;382:727–733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero J.R., Newland J.G. Viral meningitis and encephalitis: traditional and emerging viral agents. Semin. Pediatr. Infect. Dis. 2003;14:72–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">12881794</ArticleId></ArticleIdList></Reference><Reference><Citation>Royston L., Tapparel C. Rhinoviruses and respiratory enteroviruses: not as simple as ABC. Viruses. 2016;8:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4728576</ArticleId><ArticleId IdType="pubmed">26761027</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Wang X., Blau D.M., Caballero M.T., Feikin D.R., Gill C.J., et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399:2047–2064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7613574</ArticleId><ArticleId IdType="pubmed">35598608</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Li Y., Deloria-Knoll M., Madhi S.A., Cohen C., Arguelles V.L., et al. Global burden of acute lower respiratory infection associated with human parainfluenza virus in children younger than 5 years for 2018: a systematic review and meta-analysis. Lancet Glob. Health. 2021;9:e1077–e1087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8298256</ArticleId><ArticleId IdType="pubmed">34166626</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Li Y., Deloria-Knoll M., Madhi S.A., Cohen C., Ali A., et al. Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study. Lancet Glob. Health. 2021;9:e33–e43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7783516</ArticleId><ArticleId IdType="pubmed">33248481</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2017 Influenza Collaborators Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respir. Med. 2019;7:69–89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6302221</ArticleId><ArticleId IdType="pubmed">30553848</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel D., Hui H.C., Doerffler E., Clarke M.O., Chun K., Zhang L., et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of ebola and emerging viruses. J. Med. Chem. 2017;60:1648–1661.</Citation><ArticleIdList><ArticleId IdType="pubmed">28124907</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (Remdesivir) for Treatment of COVID-19. Food and Drug Administration; 2020.</Citation></Reference><Reference><Citation>Agostini M.L., Andres E.L., Sims A.C., Graham R.L., Sheahan T.P., Lu X., et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5844999</ArticleId><ArticleId IdType="pubmed">29511076</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruijssers A.J., George A.S., Schafer A., Leist S.R., Gralinksi L.E., Dinnon K.H., 3rd, et al. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep. 2020;32</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7340027</ArticleId><ArticleId IdType="pubmed">32668216</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheahan T.P., Sims A.C., Graham R.L., Menachery V.D., Gralinski L.E., Case J.B., et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 2017;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567817</ArticleId><ArticleId IdType="pubmed">28659436</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheahan T.P., Sims A.C., Leist S.R., Schafer A., Won J., Brown A.J., et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 2020;11:222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6954302</ArticleId><ArticleId IdType="pubmed">31924756</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X., Muruato A.E., Zhang X., Lokugamage K.G., Fontes-Garfias C.R., Zou J., et al. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nat. Commun. 2020;11:5214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7567097</ArticleId><ArticleId IdType="pubmed">33060595</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye W., Yao M., Dong Y., Ye C., Wang D., Liu H., et al. Remdesivir (GS-5734) impedes enterovirus replication through viral RNA synthesis inhibition. Front. Microbiol. 2020;11:1105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7304253</ArticleId><ArticleId IdType="pubmed">32595613</ArticleId></ArticleIdList></Reference><Reference><Citation>Radoshitzky S.R., Iversen P., Lu X., Zou J., Kaptein S.J.F., Stuthman K.S., et al. Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro. Sci. Rep. 2023;13:3131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9950143</ArticleId><ArticleId IdType="pubmed">36823196</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackman R.L., Hui H.C., Perron M., Murakami E., Palmiotti C., Lee G., et al. Prodrugs of a 1′-CN-4-Aza-7,9-dideazaadenosine C-nucleoside leading to the discovery of remdesivir (GS-5734) as a potent inhibitor of respiratory syncytial virus with efficacy in the african green monkey model of RSV. J. Med. Chem. 2021;64:5001–5017.</Citation><ArticleIdList><ArticleId IdType="pubmed">33835812</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo M.K., Jordan R., Arvey A., Sudhamsu J., Shrivastava-Ranjan P., Hotard A.L., et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci. Rep. 2017;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5338263</ArticleId><ArticleId IdType="pubmed">28262699</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho A., Saunders O.L., Butler T., Zhang L., Xu J., Vela J.E., et al. Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg. Med. Chem. Lett. 2012;22:2705–2707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7126871</ArticleId><ArticleId IdType="pubmed">22446091</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackman R.L., Kalla R.V., Babusis D., Pitts J., Barrett K.T., Chun K., et al. Discovery of GS-5245 (obeldesivir), an oral prodrug of nucleoside GS-441524 that exhibits antiviral efficacy in SARS-CoV-2-infected african green monkeys. J. Med. Chem. 2023;66:11701–11717.</Citation><ArticleIdList><ArticleId IdType="pubmed">37596939</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross R.W., Woolsey C., Chu V.C., Babusis D., Bannister R., Vermillion M.S., et al. Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus. Science. 2024;383</Citation><ArticleIdList><ArticleId IdType="pubmed">38484056</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C.J., Tchesnokov E.P., Feng J.Y., Porter D.P., Gotte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J. Biol. Chem. 2020;295:4773–4779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7152756</ArticleId><ArticleId IdType="pubmed">32094225</ArticleId></ArticleIdList></Reference><Reference><Citation>Dangerfield T.L., Huang N.Z., Johnson K.A. Remdesivir is effective in combating COVID-19 because it is a better substrate than ATP for the viral RNA-dependent RNA polymerase. iScience. 2020;23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7695572</ArticleId><ArticleId IdType="pubmed">33283177</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone B.F., Perry J.K., Olinares P.D.B., Lee H.W., Chen J., Appleby T.C., et al. Structural basis for substrate selection by the SARS-CoV-2 replicase. Nature. 2023;614:781–787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9891196</ArticleId><ArticleId IdType="pubmed">36725929</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C.J., Tchesnokov E.P., Woolner E., Perry J.K., Feng J.Y., Porter D.P., et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 2020;295:6785–6797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7242698</ArticleId><ArticleId IdType="pubmed">32284326</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchesnokov E.P., Gordon C.J., Woolner E., Kocinkova D., Perry J.K., Feng J.Y., et al. Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. J. Biol. Chem. 2020;295:16156–16165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7681019</ArticleId><ArticleId IdType="pubmed">32967965</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokic G., Hillen H.S., Tegunov D., Dienemann C., Seitz F., Schmitzova J., et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat. Commun. 2021;12:279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804290</ArticleId><ArticleId IdType="pubmed">33436624</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Wang H., Liu Q., Li R., Gao Y., Fang X., et al. Remdesivir overcomes the S861 roadblock in SARS-CoV-2 polymerase elongation complex. Cell Rep. 2021;37</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8498683</ArticleId><ArticleId IdType="pubmed">34653416</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo J.P.K., Dangerfield T.L., Taylor D.W., Johnson K.A. Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication. Mol. Cell. 2021;81:1548–1552.e1544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7843106</ArticleId><ArticleId IdType="pubmed">33631104</ArticleId></ArticleIdList></Reference><Reference><Citation>Seifert M., Bera S.C., van Nies P., Kirchdoerfer R.N., Shannon A., Le T.T., et al. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective. Elife. 2021;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8497053</ArticleId><ArticleId IdType="pubmed">34617885</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel D.S., Hui H.C., Pitts J., Vermillion M.S., Ishida K., Rautiola D., et al. Discovery of GS-7682, a novel 4′-cyano-modified C-nucleoside prodrug with broad activity against pneumo- and picornaviruses and efficacy in RSV-infected African green monkeys. J. Med. Chem. 2024 doi: 10.1021/acs.jmedchem.4c00899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.4c00899</ArticleId><ArticleId IdType="pubmed">39018526</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassetti M.C., Pierson T.C., Patterson L.J., Bok K., DeRocco A.J., Deschamps A.M., et al. Prototype pathogen approach for vaccine and monoclonal antibody development: a critical component of the NIAID plan for pandemic preparedness. J. Infect. Dis. 2023;227:1433–1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384504</ArticleId><ArticleId IdType="pubmed">35876700</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P. Structure of replicating SARS-CoV-2 polymerase. Nature. 2020;584:154–156.</Citation><ArticleIdList><ArticleId IdType="pubmed">32438371</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020;368:779–782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164392</ArticleId><ArticleId IdType="pubmed">32277040</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong P., Kortus M.G., Nix J.C., Davis R.E., Peersen O.B. Structures of coxsackievirus, rhinovirus, and poliovirus polymerase elongation complexes solved by engineering RNA mediated crystal contacts. PLoS One. 2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648537</ArticleId><ArticleId IdType="pubmed">23667424</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Lou Z., Miao Y., Yu Y., Dong H., Peng W., et al. Structures of EV71 RNA-dependent RNA polymerase in complex with substrate and analogue provide a drug target against the hand-foot-and-mouth disease pandemic in China. Protein Cell. 2010;1:491–500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4875138</ArticleId><ArticleId IdType="pubmed">21203964</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman M.S.A., Liu C., Fung A., Behera I., Jordan P., Rigaux P., et al. Structure of the respiratory syncytial virus polymerase complex. Cell. 2019;179:193–204.e114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7111336</ArticleId><ArticleId IdType="pubmed">31495574</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J., Qian X., Lattmann S., El Sahili A., Yeo T.H., Jia H., et al. Structure of the human metapneumovirus polymerase phosphoprotein complex. Nature. 2020;577:275–279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6949429</ArticleId><ArticleId IdType="pubmed">31698413</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdella R., Aggarwal M., Okura T., Lamb R.A., He Y. Structure of a paramyxovirus polymerase complex reveals a unique methyltransferase-CTD conformation. Proc. Natl. Acad. Sci. U. S. A. 2020;117:4931–4941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7060699</ArticleId><ArticleId IdType="pubmed">32075920</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J., Ouizougun-Oubari M., Wang L., Zhai G., Wu D., Lin Z., et al. Structural basis for dimerization of a paramyxovirus polymerase complex. Nat. Commun. 2024;15:3163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11009304</ArticleId><ArticleId IdType="pubmed">38605025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouba T., Drncova P., Cusack S. Structural snapshots of actively transcribing influenza polymerase. Nat. Struct. Mol. Biol. 2019;26:460–470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610713</ArticleId><ArticleId IdType="pubmed">31160782</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouba T., Vogel D., Thorkelsson S.R., Quemin E.R.J., Williams H.M., Milewski M., et al. Conformational changes in Lassa virus L protein associated with promoter binding and RNA synthesis activity. Nat. Commun. 2021;12:7018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8639829</ArticleId><ArticleId IdType="pubmed">34857749</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwinghammer K., Cheung A.C., Morozov Y.I., Agaronyan K., Temiakov D., Cramer P. Structure of human mitochondrial RNA polymerase elongation complex. Nat. Struct. Mol. Biol. 2013;20:1298–1303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4321815</ArticleId><ArticleId IdType="pubmed">24096365</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C.J., Lee H.W., Tchesnokov E.P., Perry J.K., Feng J.Y., Bilello J.P., et al. Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir. J. Biol. Chem. 2022;298</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8695323</ArticleId><ArticleId IdType="pubmed">34953856</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C.J., Tchesnokov E.P., Schinazi R.F., Gotte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J. Biol. Chem. 2021;297</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8110631</ArticleId><ArticleId IdType="pubmed">33989635</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchesnokov E.P., Feng J.Y., Porter D.P., Gotte M. Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses. 2019;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6520719</ArticleId><ArticleId IdType="pubmed">30987343</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens L.J., Pruijssers A.J., Lee H.W., Gordon C.J., Tchesnokov E.P., Gribble J., et al. Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. Sci. Transl. Med. 2022;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9097878</ArticleId><ArticleId IdType="pubmed">35482820</ArticleId></ArticleIdList></Reference><Reference><Citation>Peersen O.B. A comprehensive superposition of viral polymerase structures. Viruses. 2019;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6723251</ArticleId><ArticleId IdType="pubmed">31412589</ArticleId></ArticleIdList></Reference><Reference><Citation>Michailidis E., Marchand B., Kodama E.N., Singh K., Matsuoka M., Kirby K.A., et al. Mechanism of inhibition of HIV-1 reverse transcriptase by 4′-Ethynyl-2-fluoro-2′-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J. Biol. Chem. 2009;284:35681–35691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790999</ArticleId><ArticleId IdType="pubmed">19837673</ArticleId></ArticleIdList></Reference><Reference><Citation>Michailidis E., Huber A.D., Ryan E.M., Ong Y.T., Leslie M.D., Matzek K.B., et al. 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J. Biol. Chem. 2014;289:24533–24548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4148878</ArticleId><ArticleId IdType="pubmed">24970894</ArticleId></ArticleIdList></Reference><Reference><Citation>Salie Z.L., Kirby K.A., Michailidis E., Marchand B., Singh K., Rohan L.C., et al. Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) Proc. Natl. Acad. Sci. U. S. A. 2016;113:9274–9279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4995989</ArticleId><ArticleId IdType="pubmed">27489345</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan P.C., Stevens S.K., Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir. Chem. Chemother. 2018;26 doi: 10.1177/2040206618764483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2040206618764483</ArticleId><ArticleId IdType="pmc">PMC5890544</ArticleId><ArticleId IdType="pubmed">29562753</ArticleId></ArticleIdList></Reference><Reference><Citation>Agostini M.L., Pruijssers A.J., Chappell J.D., Gribble J., Lu X., Andres E.L., et al. Small-molecule antiviral beta-d-N(4)-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J. Virol. 2019;93</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6880162</ArticleId><ArticleId IdType="pubmed">31578288</ArticleId></ArticleIdList></Reference><Reference><Citation>Urakova N., Kuznetsova V., Crossman D.K., Sokratian A., Guthrie D.B., Kolykhalov A.A., et al. beta-d-N(4)-Hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J. Virol. 2018;92</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5774879</ArticleId><ArticleId IdType="pubmed">29167335</ArticleId></ArticleIdList></Reference><Reference><Citation>Toots M., Yoon J.J., Cox R.M., Hart M., Sticher Z.M., Makhsous N., et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. 2019;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6848974</ArticleId><ArticleId IdType="pubmed">31645453</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon J.J., Toots M., Lee S., Lee M.E., Ludeke B., Luczo J.M., et al. Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob. Agents Chemother. 2018;62</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105843</ArticleId><ArticleId IdType="pubmed">29891600</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y., Hong Z., et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 2000;6:1375–1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">11100123</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabinger F., Stiller C., Schmitzova J., Dienemann C., Kokic G., Hillen H.S., et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 2021;28:740–746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8437801</ArticleId><ArticleId IdType="pubmed">34381216</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone B., Chen J., Wang Q., Llewellyn E., Choi Y.J., Olinares P.D.B., et al. Structural basis for backtracking by the SARS-CoV-2 replication-transcription complex. Proc. Natl. Acad. Sci. U. S. A. 2021;118</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8126829</ArticleId><ArticleId IdType="pubmed">33883267</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon A., Fattorini V., Sama B., Selisko B., Feracci M., Falcou C., et al. A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase. Nat. Commun. 2022;13:621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8810794</ArticleId><ArticleId IdType="pubmed">35110538</ArticleId></ArticleIdList></Reference><Reference><Citation>Sourimant J., Lieber C.M., Aggarwal M., Cox R.M., Wolf J.D., Yoon J.J., et al. 4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science. 2022;375:161–167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9206510</ArticleId><ArticleId IdType="pubmed">34855509</ArticleId></ArticleIdList></Reference><Reference><Citation>Biteau N.G., Amichai S.A., Azadi N., De R., Downs-Bowen J., Lecher J.C., et al. Synthesis of 4′-substituted carbocyclic uracil derivatives and their monophosphate prodrugs as potential antiviral agents. Viruses. 2023;15:544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9962574</ArticleId><ArticleId IdType="pubmed">36851758</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G., Dyatkina N., Prhavc M., Williams C., Serebryany V., Hu Y., et al. Synthesis and anti-HCV activities of 4′-fluoro-2′-substituted uridine triphosphates and nucleotide prodrugs: discovery of 4′-fluoro-2′- C-methyluridine 5′-phosphoramidate prodrug (AL-335) for the treatment of hepatitis C infection. J. Med. Chem. 2019;62:4555–4570.</Citation><ArticleIdList><ArticleId IdType="pubmed">30951311</ArticleId></ArticleIdList></Reference><Reference><Citation>Deval J., Hong J., Wang G., Taylor J., Smith L.K., Fung A., et al. Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2′-fluoro-4′-chloromethyl-cytidine triphosphate. PLoS Pathog. 2015;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4476725</ArticleId><ArticleId IdType="pubmed">26098424</ArticleId></ArticleIdList></Reference><Reference><Citation>Deval J., Fung A., Stevens S.K., Jordan P.C., Gromova T., Taylor J.S., et al. Biochemical effect of resistance mutations against synergistic inhibitors of RSV RNA polymerase. PLoS One. 2016;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4862670</ArticleId><ArticleId IdType="pubmed">27163448</ArticleId></ArticleIdList></Reference><Reference><Citation>Klumpp K., Kalayanov G., Ma H., Le Pogam S., Leveque V., Jiang W.R., et al. 2′-deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-alpha-hydroxyl groups. J. Biol. Chem. 2008;283:2167–2175.</Citation><ArticleIdList><ArticleId IdType="pubmed">18003608</ArticleId></ArticleIdList></Reference><Reference><Citation>Takamatsu Y., Tanaka Y., Kohgo S., Murakami S., Singh K., Das D., et al. 4′-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus. Hepatology. 2015;62:1024–1036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4589464</ArticleId><ArticleId IdType="pubmed">26122273</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z., Kinkade A., Behera I., Chaudhuri S., Tucker K., Dyatkina N., et al. Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs. Antivir. Res. 2017;143:151–161.</Citation><ArticleIdList><ArticleId IdType="pubmed">28412183</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger I., Fitzgerald D.J., Richmond T.J. Baculovirus expression system for heterologous multiprotein complexes. Nat. Biotechnol. 2004;22:1583–1587.</Citation><ArticleIdList><ArticleId IdType="pubmed">15568020</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieniossek C., Richmond T.J., Berger I. MultiBac: multigene baculovirus-based eukaryotic protein complex production. Curr. Protoc. Protein Sci. 2008 doi: 10.1002/0471140864.ps0520s51. Chapter 5, Unit 5 20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471140864.ps0520s51</ArticleId><ArticleId IdType="pubmed">18429060</ArticleId></ArticleIdList></Reference><Reference><Citation>Pflug A., Guilligay D., Reich S., Cusack S. Structure of influenza A polymerase bound to the viral RNA promoter. Nature. 2014;516:355–360.</Citation><ArticleIdList><ArticleId IdType="pubmed">25409142</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich S., Guilligay D., Pflug A., Malet H., Berger I., Crepin T., et al. Structural insight into cap-snatching and RNA synthesis by influenza polymerase. Nature. 2014;516:361–366.</Citation><ArticleIdList><ArticleId IdType="pubmed">25409151</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng J.Y., Du Pont V., Babusis D., Gordon C.J., Tchesnokov E.P., Perry J.K., et al. The nucleoside/nucleotide analogs tenofovir and emtricitabine are inactive against SARS-CoV-2. Molecules. 2022;27:4212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9267940</ArticleId><ArticleId IdType="pubmed">35807457</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts K.S., Dalal P., Tebben A.J., Cheney D.L., Shelley J.C. Macrocycle conformational sampling with MacroModel. J. Chem. Inf. Model. 2014;54:2680–2696.</Citation><ArticleIdList><ArticleId IdType="pubmed">25233464</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamadi F., Richards N.G.J., Guida W.C., Liskamp R., Lipton M., Caufield C., et al. Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990;11:440–467.</Citation></Reference><Reference><Citation>Appleby T.C., Perry J.K., Murakami E., Barauskas O., Feng J., Cho A., et al. Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase. Science. 2015;347:771–775.</Citation><ArticleIdList><ArticleId IdType="pubmed">25678663</ArticleId></ArticleIdList></Reference><Reference><Citation>Young T., Abel R., Kim B., Berne B.J., Friesner R.A. Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding. Proc. Natl. Acad. Sci. U. S. A. 2007;104:808–813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1783395</ArticleId><ArticleId IdType="pubmed">17204562</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel R., Young T., Farid R., Berne B.J., Friesner R.A. Role of the active-site solvent in the thermodynamics of factor Xa ligand binding. J. Am. Chem. Soc. 2008;130:2817–2831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2761766</ArticleId><ArticleId IdType="pubmed">18266362</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson M.P., Friesner R.A., Xiang Z., Honig B. On the role of the crystal environment in determining protein side-chain conformations. J. Mol. Biol. 2002;320:597–608.</Citation><ArticleIdList><ArticleId IdType="pubmed">12096912</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson M.P., Pincus D.L., Rapp C.S., Day T.J., Honig B., Shaw D.E., et al. A hierarchical approach to all-atom protein loop prediction. Proteins. 2004;55:351–367.</Citation><ArticleIdList><ArticleId IdType="pubmed">15048827</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert X., Gouet P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 2014;42:W320–W324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086106</ArticleId><ArticleId IdType="pubmed">24753421</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>